|
11. |
Fibrates, dyslipoproteinaemia and cardiovascular disease |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 561-574
Gerald Watts,
Simon Dimmitt,
Preview
|
PDF (1413KB)
|
|
摘要:
Recent epidemiological data have reaffirmed that elevated plasma triglyceride and low HDL-cholesterol levels are important risk factors for atherosclerotic vascular disease. The rationale for the clinical use of fibric acid derivatives, which are designed to correct this metabolic nexus, is now on firmer ground. The mechanism of action of fibrates on lipoprotein metabolism has recently been elucidated at the molecular level and involves the activation of peroxisome proliferator-activated receptor-1 in the liver, with the net effect of improving the plasma transport rates of several lipoproteins. Other potential anti-atherothrombotic effects include the inhibition of coagulation and enhancement of fibrinolysis, as well as the inhibition of inflammatory mediators involved in atherogenesis. These consequences probably underpin the favourable effects of fibrates seen in recent angiographic and clinical trials. Two important clinical trials on the effect of gemfibrozil (Veterans Administration-HDL-Cholesterol Intervention Trial) and bezafibrate (Bezafibrate Infarction Prevention Study) have recently been completed in subjects with elevated triglyceride, low HDL and normal or near-normal LDL-cholesterol levels. The results testify to the efficacy of these agents in decreasing the incidence of cardiovascular events, particularly in patients with multiple risk factors and plasma triglyceride levels of over 2.2 mmol/l. The findings of these trials are compared with the statin-based Air Force/Texas Coronary Atherosclerosis Prevention Study, with a recommendation that future studies in appropriately selected patients should examine the synergistic effect of the fibrate/statin combination. The absolute risk reduction in the incidence of coronary events in the Veterans Administration-HDL-Cholesterol Intervention Trial compares favourably with the statin trials. The therapeutic aspects of the efficacy and safety of fibrates are reviewed. Besides primary mixed hyperlipidaemias, particular indications for the clinical use of fibrates include type 2 diabetes, the metabolic syndrome and renal insufficiency. The St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study has suggested that fibrates may decrease the incidence of coronary events in type 2 diabetes, but this hypothesis will be more extensively tested in the Diabetes Atherosclerosis Intervention Study, Fenofibrate in Event Lowering in Diabetes Study and Lipids in Diabetes Study projects. Although significant new knowledge has accrued over the past few years concerning the fundamental and clinical aspects of fibrates, the success of these agents in clinical practice depends on the availability of methods for assessing cardiovascular risk as well as on treatment guidelines, which as presently designed and recommended may be inaccurate and suboptimal.
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
12. |
Non‐pharmacological lowering of low‐density lipoprotein by apheresis and surgical techniques |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 575-580
Robert Lees,
Linda Cashin-Hemphill,
Ann Lees,
Preview
|
PDF (388KB)
|
|
摘要:
In the past year, new data have appeared on the long-term benefits of low-density lipoprotein apheresis in severely hypercholesterolemic patients who are refractory to lipid-lowering drug therapy. Such data are critical for clinical decision-making, because they confirm the hypothesis that the dramatic reduction in low-density lipoprotein made possible by this technique produces clear-cut clinical benefits. Because of its efficacy and low incidence of side-effects, apheresis for severe drug-refractory hypercholesterolemia has superseded surgical approaches, such as liver transplantation or ileal bypass.
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
13. |
Hormone replacement therapy and cardiovascular disease |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 581-588
Mary Seed,
Preview
|
PDF (632KB)
|
|
摘要:
This year's work on hormone replacement therapy (HRT) and cardiovascular disease has been remarkable for the publication of the first randomised controlled trial of HRT use, the Heart Estrogen Replacement Study (HERS). The findings go against not only the trend of previous observational epidemiological studies, but also against findings in the very many studies which have previously shown and continue to show this year a beneficial effect of HRT on a large variety of cardiovascular risk factors, including endothelial function, here reviewed. The aspect of the effect of HRT on clotting variables is clearly crucial given the increased risk of venous thrombosis, and also increased number of cardiac events in the first 4 months of the HERS. Prothrombotic factors increase with age in women, and HRT alters these, particularly fibrinogen, factor VII, and PAI (less change with transdermal HRT) and antithrombin III. In normal women therefore the balance should be towards fibrinolysis rather than coagulation. Work has been presented in abstract for clarifying the effects of HRT on coagulation markers and grasping the problem of differences according to its route of administration. The full publications on this work are expected shortly. We are still awaiting evidence from randomized controlled trials of HRT in primary prevention; one is now recruited but will not report until 2005.
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
14. |
Dietary and pharmacological antioxidants in atherosclerosis |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 589-598
Roland Stocker,
Preview
|
PDF (861KB)
|
|
摘要:
Antioxidants that inhibit LDL oxidation are thought to be potential anti-atherogenic compounds. The results of major human randomized trials with antioxidants have, however, been disappointing, except for probucol, which consistently inhibits restenosis. Similarly, animal intervention studies show that antioxidants do not generally inhibit atherosclerosis, although some compounds provide protection. Direct evidence for the oxidation of LDL causing atherosclerosis is needed. This article summarizes results from antioxidant intervention studies, and highlights some of the key issues that need to be addressed to link biochemical changes in the arterial wall more directly to the oxidation theory of atherosclerosis.
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
15. |
Atherosclerosiscell biology and liporoteins |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 599-614
&NA;,
Preview
|
PDF (2549KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
16. |
Therapy and clinical trials |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 615-624
Preview
|
PDF (1177KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
17. |
Nutrition |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 625-626
Michael,
Preview
|
PDF (141KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
18. |
Genetics and molecular biology |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 627-630
Yonghe,
Li Guojun,
Preview
|
PDF (143KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
19. |
Lipid metabolism |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 631-634
Ian,
Young D.,
Preview
|
PDF (140KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
20. |
Hyperlipidaemia and cardiovascular disease |
|
Current Opinion in Lipidology,
Volume 10,
Issue 6,
1999,
Page 635-640
Andrey,
Preview
|
PDF (383KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:1999
数据来源: OVID
|
|